Clinical Trial Update: A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea [Phase 1]

View source ↗

Summary

Phase 1 trial of depot-formulation subcutaneous immunotherapy for rhinoconjunctivitis due to Olea europaea (olive tree) pollen has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinoconjunctivitis

Drugs mentioned

• Depot-formulation subcutaneous immunotherapy

Snippet

Sponsor: Roxall Medicina España S.A | Conditions: Rhinoconjunctivitis | Phase 1 | Status: COMPLETED